Compugen Discloses Predictive Structural Biology Infrastructure Platform for Enhanced Discovery of Novel Drugs

S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Compugen Discloses Predictive Structural Biology Infrastructure Platform for Enhanced Discovery of Novel Drugs

New capability enables computational identification of functional interaction sites of proteins

Current application aims at rational design of functional antibodies

Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Compugen Charts.

Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more Compugen Charts.

Compugen Ltd. News

Compugen to Present at Upcoming Antibody Industrial Symposium
Monday 17 June 2024 (4 weeks ago) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 30 May 2024 (2 months ago) • Edgar (US Regulatory)

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Thursday 30 May 2024 (2 months ago) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 20 May 2024 (2 months ago) • Edgar (US Regulatory)

Compugen Reports First Quarter 2024 Results
Monday 20 May 2024 (2 months ago) • PR Newswire (US)

U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip
Monday 20 May 2024 (2 months ago) • IH Market News

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
Thursday 16 May 2024 (2 months ago) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 15 May 2024 (2 months ago) • Edgar (US Regulatory)

Compugen Appoints David Silberman as Chief Financial Officer
Wednesday 15 May 2024 (2 months ago) • PR Newswire (US)

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Monday 6 May 2024 (2 months ago) • PR Newswire (US)

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Thursday 25 April 2024 (3 months ago) • PR Newswire (US)

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Wednesday 10 April 2024 (3 months ago) • PR Newswire (US)

More Compugen Ltd. News Articles

Ishr E Gv 15-30

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions